

NOV 8 2001

Sheet 1 of 3

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 1038-1191MIS:ac	SERIAL NO. 09/914,621
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Xiaomao Li et al	
		FILING DATE March 3, 2000	GROUP 1036

## U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
QW	5,149,650	Sept. 22, 1992	Wertz et al	435	243	
QW	5,589,466	Dec. 31, 1996	Felgner et al	514	44	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
QW	WO 90/11092	10-04-90	PCT	-	-	YES	NO
	WO 00/53767	09-14-00	PCT	-			
	WO 93/21310	28-10-93	PCT				
	WO 92/07940	14-05-92	PCT				
	WO 94/21797	09-29-94	PCT				
	WO 99/04010	01-28-1999	PCT				
QW	WO 96/40945	12-19-1996	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

QW	1	McIntosh, K. Et al In: Fields BN, Knipe, DM, editors. Virology, New York: Raven Press 1990: 1045-1072
	2	Katz, S.L. New Vaccine Development establishing priorities. Vol. 1. Washington: National Academic Press: 1985 397-409
	3	Wertz, G.W. et al, Biotechnology 1992, 20: 151-176
	4	Johnson et al., J. Virol. 1987, 61: 3163-3165
	5	Pemberton et al., J. Gen. Virol. 1987, 68:2177-2182
	6	Crowe, J.E., Vaccine 1995, 13: 415-421
	7	Ulmer, Current Opinion, Invest Drugs, 1993, 2: 983-989
QW	8	Tang et al., Nature 1992, 356: 152-154
EXAMINER: <i>Sam Nguyen</i>		DATE CONSIDERED: 2/27/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1191 MIS:ac	SERIAL NO. 09/914,621
	APPLICANT Xiaomao Li et al	
	FILING DATE March 3, 2000	GROUP 16.36

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
9	Furth et al. Analytical Biochemistry, 1992, 205: 365-368	
10	Pizzorno et al., J. Virol. 1988, 62:1167-1179	
11	Chapman, B.S. et al, Nucl. Acids Res. 1991, 19: 3979-3986	
12	Green, S. Et al., Nucl. Acids Res. 1988, 16:369	
13	Breathnack, R. et al., Nucl. Acids Res. 1983, 11:7119-7136	
14	Graham, B.S. et al., J. Mod. Virol. 1988 26: 153-162	
15	Nabel, G.J. et al Proc. Natl. Acad. Sci. USA 90:11307-11311, 1993	
16	Du, R.P. et al 1994, Biotechnology 12: 813-818	
17	Prince, G.A. et al, 1978. Ame J. Pathol. 93: 771-790	
18	Karasuyama & Melchers, Eur. J. Immunol. 18, 97-104, 1988.	
19	Wilde, David B. et al., 1983, J. Immunol. 131:2178-2183	
20	Ledbetter, J.A. et al., 1980, J. Exp. Med. 152:280-295	
21	Ozato Keiko et al, 1982, Transplantation 34: 113-118	
22	Davis et al., Vaccine 1994, 12:1503-1509.	
23	Chanock, Robert M. et al, Pediatrics Vol. 90 No. 1, July 1992, pp 137-142.	
24	Prince et al, J. Virol., 61:1851-1854, 1975	
24	Crowe et al, PNAS 91: 1386-1390, 1994	
25	Prince et al, <del>J. Virol. 55:517</del> Virus Res. 3: 193-206, 1985.	
26	Groothuis et al, N. Engl. J. Med. 329:1524-1530, 1993	
27	Walsh et al, J. Infec. Dis., 155: 1198-1204, 1987	
28	Paradiso et al, Pediatr. Infect. Dis. J. 13:792-798, 1994	
EXAMINER: <i>[Signature]</i>		DATE CONSIDERED: 2/27/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

